HS-20137

Phase 2

Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

HNPHYPhase 2

HS-20137 Phase 2 Est. Readout

HS-20137• Moderate-to-severe Plaque Psoriasis390

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Moderate-to-severe Plaque Psoriasis

View Full Landscape

Drug Information

Target Indication

Moderate-to-severe Plaque Psoriasis

Clinical Trial

NCT07879885

Last updated: 10/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HNPHY

Hansoh Pharmaceutical Group Co Limited/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

FlumatinibPhase 3

CML, CML-CP,MMR,TKI

HS-20093Phase 3

Metastasis Castration Resistant Prostate Cancer(mCRPC)

Gemcitabine combined with docetaxelPhase 3

Osteosarcoma

AumolertinibPhase 3

Non-small Cell Lung Cancer

HS-20117Phase 3

Non-Squamous Non-Small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts